Filing summary
Entity note: The supplied filing is Synaptogenix, Inc.’s Form 10-Q, not a filing for TAO Synergies Inc. It covers the quarter and nine months ended September 30, 2023; the financial statements are unaudited.
Business context and reporting period
Synaptogenix is a clinical-stage biopharmaceutical company focused primarily on Bryostatin-1 for Alzheimer’s disease (AD), with other potential programs including Fragile X syndrome and multiple sclerosis (MS). The company reported no product revenue in the supplied financial statements.
Financial results and liquidity
| Metric | Three months ended September 30, 2023 | Nine months ended September 30, 2023 |
|---|---|---|
| Research and development expense | $212,103 | $1.397 million |
| General and administrative expense | $1.218 million | $4.784 million |
| Total operating expenses | $1.430 million | $6.181 million |
| Other income, net | $2.193 million | $1.139 million |
| Net result before preferred dividends | $763,203 income | $5.043 million loss |
| Net loss attributable to common stockholders | $361,425 | $12.550 million |
| Basic and diluted loss per common share | $0.03 | $1.48 |
At September 30, 2023, cash and cash equivalents were $31.728 million, current assets were $32.341 million, current liabilities were $1.818 million, and working capital was $30.523 million. Cash declined $5.751 million from year-end 2022. For the first nine months, operating cash use was $4.107 million, investing cash use was $2,707, and financing cash use was $1.641 million. No conventional debt balance is reported; significant obligations include redeemable Series B preferred stock and related accrued payments. Preferred stock had a $9 million liquidation preference plus accrued dividends.
Management said approximately $29.5 million of cash at the report date was expected to fund projected operating needs and financial commitments for at least 12 months. The company expects it will need additional capital for further development. The filing gives no gross margin or product revenue figures.
Changes versus the prior comparable periods
- For the first nine months, total operating expenses fell approximately 39.7% year over year; R&D expense decreased 71.6%, primarily because the AD Phase 2 study was materially concluded by the end of 2022 and the dose-ranging study was discontinued. G&A expense decreased 10.3%.
- Nine-month net loss narrowed from $10.056 million to $5.043 million before preferred dividends. The common-stockholder loss rose to $12.550 million, reflecting $1.814 million of preferred dividends and a $5.693 million deemed dividend related to preferred-stock extinguishment.
- Quarterly operating expenses fell 54.9% year over year. The quarter reported $763,203 of net income before preferred dividends, but a $361,425 loss attributable to common stockholders after preferred dividends.
- Cash and cash equivalents decreased from $37.478 million at December 31, 2022 to $31.728 million at September 30, 2023. Common shares outstanding increased from 7.267 million to 17.511 million during that period, principally reflecting preferred-stock conversions and related shares.
Outlook, risks, contingencies and unusual items
- Clinical results: The confirmatory Phase 2 AD study failed to achieve statistical significance on its primary endpoint. Management reported that nearly all prespecified secondary endpoints were statistically significant in the subgroup with baseline MMSE-2 scores of 10–14; the broader population and the low-to-moderately severe subgroup did not meet the reported secondary-endpoint criteria. These subgroup and post hoc findings do not change the primary-endpoint result.
- Program status and costs: The Fragile X IND is on FDA clinical hold pending further pharmacokinetic and pharmacodynamic analyses. Synaptogenix is evaluating next steps. A Phase 1 MS trial agreement with Cleveland Clinic carries estimated costs of approximately $2 million; approximately $375,000 had been paid by September 30, 2023. The company is evaluating alternatives to produce synthetic Bryostatin-1; estimated cost to initiate production of sufficient quantities was approximately $1.5 million.
- Preferred financing and dilution: Series B preferred stock carries a 7% annual dividend, compounded monthly, and scheduled redemption installments; the rate may rise to 15% upon specified triggering events. The company accrued approximately $1.527 million of installment payments due in cash or shares at quarter-end. The terms permit share settlement subject to limitations, creating potential dilution. The filing reported that 2.88 million common shares were issued after quarter-end through November 9, 2023, in partial satisfaction of the accrued redemption liability.
- Nasdaq listing: Nasdaq granted an additional compliance period through April 22, 2024, to meet the $1.00 minimum bid-price requirement. Failure to regain compliance could lead to delisting, subject to appeal.
- Capital and supply risks: Management warns that further financing may be needed and may be unavailable or dilutive, or may impose restrictive terms or require relinquishing technology rights. Existing NCI bryostatin supply is insufficient for all trials required to seek FDA approval; additional supply arrangements or another source would be needed. The company also identifies clinical, regulatory, competition, licensing, and raw-material risks.
- Subsequent event: On October 31, 2023, the company agreed to acquire Cannasoul preferred shares and a convertible preferred note of up to approximately $1.438 million, with up to approximately $2 million of additional notes conditional on future performance goals.
- Controls and contingencies: Management concluded disclosure controls were ineffective because of material weaknesses involving segregation of duties, period-end reporting and documentation, and IT general controls. The filing reports no legal proceedings and no indemnification claims, but describes uncapped reciprocal indemnities related to the separation and tax matters.
Important facts for investors to verify
- Confirm the filing and issuer identity: this 10-Q is for Synaptogenix, Inc. (SNPX), not TAO Synergies Inc.
- Review the full Phase 2 AD data, especially the failed primary endpoint, subgroup analyses, and whether further trials are planned and funded.
- Track preferred-stock installment payments, cash-versus-share settlements, accrued dividends, conversion terms, and resulting dilution.
- Assess the stated cash runway against the development plans, the Cannasoul transaction, and the company’s potential need for additional capital.
- Monitor Nasdaq’s April 22, 2024 bid-price deadline and remediation status.
- Evaluate progress addressing the disclosed control weaknesses and confirm the status and cost of Bryostatin-1 supply and the Fragile X clinical hold.